COVID-19 Vaccine Reactogenicity and Vaccine Attitudes Among Children and Parents/Guardians After Multisystem Inflammatory Syndrome in Children or COVID-19 Hospitalization: September 2021-May 2022

• Type of Material: Article
• Authors: Anna R Yousaf, CDC COVID-19 Response Team; Amber Kunkel, Centers for Disease Control and Prevention, Atlanta; Joseph Y Abrams, CDC COVID-19 Response Team; Ami B Shah, CDC COVID-19 Response Team; Teresa A Hammett, CDC COVID-19 Response Team; Kathryn E Arnold, CDC COVID-19 Response Team; Yajira L Beltran, Orlando Health Arnold Palmer Hospital for Children; Federico R Laham, Orlando Health Arnold Palmer Hospital for Children; Carol Kao, Emory University; David A Hunstad, Washington University; Laila Hussaini, Emory University; Nadine Baida, Emory University; Luis Salazar, Emory University; Maria A Perez, Emory University; Christina Rostad, Emory University; Shana Godfred-Cato, CDC COVID-19 Response Team; Angela Campbell, Emory University; Ermias Belay, CDC COVID-19 Response Team
• Language: English
• Date: 2023-03-01
• Publisher: LIPPINCOTT WILLIAMS & WILKINS
• Publication Version: Final Published Version
• Copyright Statement: © 2022 Wolters Kluwer Health, Inc. All rights reserved.
• Final Published Version (URL): http://dx.doi.org/10.1097/INF.0000000000003803
• Title of Journal or Parent Work: PEDIATRIC INFECTIOUS DISEASE JOURNAL
• Volume: 42
• Issue: 3
• Start Page: 252
• End Page: 259
• Keywords: PRACTICES INTERIM RECOMMENDATION; Immunology; Pediatrics; Infectious Diseases; adverse events; MIS-C; vaccine; SAFETY; MESSENGER-RNA VACCINATION; ADVISORY-COMMITTEE; COVID-19; Science & Technology; UNITED-STATES; DECEMBER; Life Sciences & Biomedicine
• Research Categories: Health Sciences, Medicine and Surgery

Abstract

Background: Multisystem inflammatory syndrome in children (MIS-C) is a multiorgan hyperinflammatory condition following SARS-CoV-2 infection. Data on COVID-19 vaccine adverse events and vaccine attitudes in children with prior MIS-C are limited. We described characteristics associated with COVID-19 vaccination, vaccine adverse events and vaccine attitudes in children with a history of MIS-C or COVID-19 and their parents/guardians. Methods: We enrolled children previously hospitalized for MIS-C or COVID-19 from 3 academic institutions. We abstracted charts and interviewed children and parents/guardians regarding vaccine adverse events and acceptability. Results: Of 163 vaccine-eligible children enrolled with a history of MIS-C and 70 with history of COVID-19, 51 (31%) and 34 (49%), respectively, received mRNA COVID-19 vaccine a median of 10 (Interquartile Range 6-13) months after hospital discharge. Among 20 children with MIS-C and parents/guardians who provided interviews, local injection site reaction of brief duration (mean 1.8 days) was most commonly reported; no children required medical care within 2 weeks postvaccination. Vaccine survey results of interviewed, vaccinated children and their parents/guardians: of 20 children with MIS-C and 15 children with COVID-19, 17 (85%) and 13 (87%), respectively, listed doctors in the top 3 most trusted sources for vaccine information; 13 (65%) and 9 (60%) discussed vaccination with their doctor. Conclusions: COVID-19 vaccination was well tolerated in children with prior MIS-C or COVID-19 participating in our investigation. Parents/guardians regarded their children's doctors as a trusted source of information for COVID-19 vaccines, and most vaccinated children's parents/guardians had discussed COVID-19 vaccination for their child with their doctor.